← Home / Beam Therapeutics Inc. (BEAM)
Stock Analysis
Beam Therapeutics Inc. (BEAM)
BEAM
BEAM · Healthcare • Biotech
26.49 +1.81%
Track BEAM in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when BEAM price is:
52W Range Position
48%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-07-31 11:41 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
28.05
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
7
●
Financial Results
HIGH
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
(Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.
8-K Filing • SEC EDGAR
What's Driving BEAM?
📈 Technical recovery is improving
Momentum is Neutral. Watch 28.05 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
38.8
Price Chart
BEAM — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-30
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$2.7B
Company size
EV
$2.5B
Debt-adjusted value
P/E
-41.8
Not meaningful
P/S
16.6
Premium
P/B
2.3
Balanced
EV/Sales
15.5
Premium
EV/EBIT
-6.8
Not meaningful
P/FCF
-7.1
Not meaningful
FCF Yield
-14.10%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
31.74M
↗ Strong
📈 Net Income
-94.32M
↘ Negative
🧮 EPS (Basic)
-0.91
↘ Negative
Beam Therapeutics Inc.
Healthcare • Biotech
Related Opportunities